Core Viewpoint - Jingtai Technology has officially entered the stage of scalable value realization, marking a significant milestone in its growth trajectory as it becomes the first profitable AI application company listed in Hong Kong [5][7]. Financial Performance - In 2025, Jingtai Technology achieved a revenue of 803 million RMB, representing a year-on-year growth of 201.2%. The net profit reached 135 million RMB, with an adjusted net profit of 258 million RMB, indicating its first annual profitability [5]. - As of December 31, 2025, the company had a cash balance of 7.069 billion RMB and a net issuance of convertible bonds amounting to 2.562 billion RMB, providing a solid financial foundation for ongoing R&D investments [6]. Business Development - The number of revenue-generating clients increased by 62% year-on-year, covering 17 of the top 20 global pharmaceutical companies, with cumulative cooperation amounts reaching hundreds of billions of RMB [6]. - Jingtai Technology has empowered and incubated over five first-in-class/best-in-class innovative pipelines, entering clinical and IND-enabling stages across various disease areas, including oncology and chronic diseases [6]. Strategic Upgrades - The AI4S smart solution business saw a revenue increase of 62.6% to 265 million RMB in 2025, reflecting a strategic upgrade from traditional delivery to a comprehensive intelligent R&D system [12]. - The company has transitioned its business model from single project services to a strategy of "platform licensing + joint development + milestone revenue," laying a solid foundation for sustainable growth [13]. Technological Integration - Jingtai Technology's "AI + Robotics + Multi-Agent" system has created a self-evolving R&D model, enhancing efficiency in drug discovery and development [15][19]. - The company has developed over 200 industry-specific AI models, covering the entire chain from target discovery to preclinical candidate screening, supported by a robust data asset system [20]. Cross-Industry Expansion - Jingtai Technology is accelerating the application of its core capabilities into consumer health and new materials sectors, demonstrating the platform's universal value [22]. - In the consumer health sector, the company has registered innovative external molecules for hair growth, achieving significant market recognition [22]. - In the photovoltaic sector, a strategic partnership with Jinko Solar aims to develop AI-driven high-throughput solar cell manufacturing lines, showcasing the company's commitment to next-generation technology [24][25]. Future Outlook - The company plans to deepen the flywheel effect of technological iteration, leveraging its AI models and automated laboratories to maintain its leading position in the AI for Science field while expanding into broader sectors [27].

Core Viewpoint - The company has successfully developed and validated two innovative topical active ingredients for hair loss prevention and regrowth, leveraging its industry-leading AI molecular discovery platform, addressing a growing global market of over 2.5 billion people suffering from hair loss [1] Group 1: Product Development - The two active ingredients developed are small molecule Remeanagen™ (XTP-118) and peptide AquaKine™ (XTP-016) [1] - The combination of these "twin star" molecules has shown significant improvements in hair regrowth and prevention efficacy, safety, and onset speed compared to existing products [1] - Both molecules have successfully passed the INCI registration in the United States, and the combined product Groland has received FDA cosmetic registration [1] Group 2: Market Potential - The global hair loss population is over 2.5 billion and continues to grow, indicating a substantial market opportunity for effective products [1] - The company's AI platform is now entering the consumer health sector, which has significant potential for growth alongside its ongoing drug development for major diseases [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 XtalPi Holdings Limited （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：2228） 晶泰控股有限公司 自願性公告 晶泰AI創新研發平台成功開發生髮「雙子星」新分子， 獲得關鍵國際認證 本公告由晶泰控股有限公司（「本公司」或「晶泰」，連同其子公司統稱「本集團」） 自願作出。本公告旨在讓本公司股東及潛在投資者知悉本集團的最新業務發 展狀況。 根據聯合國人口預測及艾瑞咨詢，目前全球脫髮人群超過25億並逐年增加，但 市場缺乏有效產品。本公司董事會（「董事會」）欣然宣佈，本集團憑借其行業領 先的AI分子發現平台，成功開發並驗證了兩款兼具防脫和生髮的創新外用功效 成分 — 小分子Remeanagen™ (XTP-118)及多肽AquaKine™ (XTP-016）。這對「雙子 星」分子的聯用配方，經嚴謹人體實驗證明，在生髮防脫效果、安全性及起效 速度上均顯著超越現 ...